Drug intelligence / Profile preview

UBP-3005

Development stage: Preclinical
Lead developer: UWELL Biopharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UBP-3005 is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy being developed by UWELL Biopharma for the treatment of Non-Hodgkin lymphoma. It is part of the UWC19 program, which includes several regional variants (UBP-3001 through UBP-3005) tailored for different geographies. The therapy involves engineering a patient's T cells to express a chimeric antigen receptor that specifically recognizes and eliminates CD19-expressing malignant B cells. As of the latest pipeline information, the asset is in the preclinical CAR engineering stage.

Other names: UWC19UWC-19UWC 19

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on UBP-3005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBP-3005.

Explore the full profile